Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 228,400,057 papers from all fields of science
Search
Sign In
Create Free Account
0.8 ML Filgrastim 0.6 MG/ML Prefilled Syringe [Neupogen]
Known as:
FILGRASTIM 480 ug in 0.8 mL SUBCUTANEOUS INJECTION, SOLUTION [NEUPOGEN]
, Neupogen 480 MCG per 0.8 ML Prefilled Syringe
, 0.8 ML Neupogen 0.6 MG/ML Prefilled Syringe
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
9 relations
Acetic Acid
Filgrastim
Neupogen
Polysorbate 80
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract P4-12-07: Cost-minimization of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar ZARXIO® over NEUPOGEN®, NEULASTA®, and NEULASTA/ONPRO®: Breast cancer case study
A. McBride
,
K. Campbell
,
Mohan Bikkina
,
K. MacDonald
,
I. Abraham
,
S. Balu
2018
Corpus ID: 80070190
RATIONALE & OBJECTIVES: Biosimilar filgrastim may offer significant cost advantages over originator filgrastim and pegfilgrastim…
Expand
2017
2017
Biosimilar filgrastim (leucostim®) have similar efficacy in steady-state hematopoietic progenitor cell mobilization compared to original filgrastim (neupogen®) and lenograstim (granocyte®): A…
Ömür Kayikçi
,
E. Tekgündüz
,
+7 authors
F. Altuntaş
Transfusion and Apheresis Science
2017
Corpus ID: 25282982
2016
2016
Mobilization of hematopoietic progenitor cells from allogeneic healthy donors using a new biosimilar G‐CSF (Zarzio®)
M. Antelo
,
A. Zabalza
,
+5 authors
E. Olavarría
Journal of clinical apheresis
2016
Corpus ID: 22736558
Peripheral blood progenitor cells (PBPCs) have become the major source of hematopoietic progenitor cells for allogeneic…
Expand
2016
2016
Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR)
Alberto Bongiovanni
,
M. Monti
,
+9 authors
T. Ibrahim
Supportive Care in Cancer
2016
Corpus ID: 3785953
PurposeAnthracycline and ifosfamide-based chemotherapy represents a widely used regimen both in early and advanced settings in…
Expand
2015
2015
The evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34 + peripheral hematopoietic stem cell mobilisation…
S. Şıvgın
,
Esen Karakus
,
+6 authors
A. Unal
2015
Corpus ID: 76879496
2014
2014
Comparison of the pharmacokinetic and pharmacodynamic properties of two recombinant granulocyte colony-stimulating factor formulations after single subcutaneous administration to healthy volunteers.
A. Sveikata
,
G. Gumbrevičius
,
K. Sestakauskas
,
R. Kregždytė
,
V. Janulionis
,
Vidmantas Fokas
Medicina
2014
Corpus ID: 44303478
Highly Cited
2011
Highly Cited
2011
First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony- stimulating factor
F. Lefrère
,
A. Brignier
,
+7 authors
M. Cavazzana‐Calvo
Advances in Therapy
2011
Corpus ID: 35278793
IntroductionMobilization techniques for autologous peripheral blood stem cell (PBSC) collection include chemotherapy followed by…
Expand
2001
2001
Fallbericht zur Therapie mit Granulozyten stimulierendem Faktor beim diabetischen Fuß
O. Kreyden
,
J. Hafner
,
G. Burg
,
F. Nestle
Der Hautarzt
2001
Corpus ID: 1355541
ZusammenfassungDer diabetische Fuß entsteht durch das Zusammenwirken mehrerer pathogenetischer Faktoren: Periphere Neuropathie…
Expand
1997
1997
G-CSF bei Radiochemotherapie
M. Riepl
,
R. Fietkau
,
R. Sauer
Strahlentherapie und Onkologie (Print)
1997
Corpus ID: 45568520
ZusammenfassungHintergrundG-CSF (granulocyte-colony-stimulating-factor) beschleunigt die Teilung, Reifung und Freisetzung von…
Expand
1997
1997
472 Rechallenge chemotherapy (CT) with neupogen® (G-CSF) in relapsed small cell lung cancer
M. Vincent
,
W. Kocha
,
+6 authors
G. Goss
1997
Corpus ID: 72810200
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE